利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.024 秒)

    Treatment Of Inflammatory Lung Conditions With Aerosolized Macrolide Antibiotics
    2.
    发明申请
    Treatment Of Inflammatory Lung Conditions With Aerosolized Macrolide Antibiotics 审中-公开
    用气溶胶大环内酯类抗生素治疗炎症性肺病

    公开(公告)号：US20100029551A1

    公开(公告)日：2010-02-04

    申请号：US12533779

    申请日：2009-07-31

    申请人： Howard V. Raff ,  Ralph Niven

    发明人： Howard V. Raff ,  Ralph Niven

    IPC分类号： A61K31/7048 ,  A61P29/00 ,  A61K38/13

    CPC分类号： A61K31/7048 ,  A61K9/008 ,  A61K38/13 ,  A61K2300/00

    摘要： Provided herein are pharmaceutical compositions comprising an anti-inflammatory macrolide compound suitable for aerosolized administration to the lungs by inhalation, and methods of treating inflammatory lung conditions, particularly those characterized by chronic inflammation, by administering an aerosolized anti-inflammatory macrolide compound to the lungs by inhalation. Also provided are unit dose formulations of an anti-inflammatory macrolide for aerosolized administration to the lungs by inhalation. Advantageously, the described methods and compositions allow for the targeted, localized delivery of anti-inflammatory macrolide compounds throughout the lungs without significant systemic absorption or deposition.

    摘要翻译： 本文提供了药物组合物，其包含适于通过吸入对肺进行气雾化给药的抗炎大环内酯类化合物，以及通过以下方式治疗炎症性肺病症，特别是慢性炎症特征性的方法：通过向肺部施用气雾化抗炎大环内酯化合物 吸入 还提供了抗炎大环内酯的单位剂量制剂，用于通过吸入雾化给予肺部。 有利地，所描述的方法和组合物允许在整个肺部靶向，局部递送抗炎大环内酯化合物，而不会有显着的全身吸收或沉积。

    TACROLIMUS COMPOSITIONS FOR AEROSOL ADMINISTRATION
    3.
    发明申请
    TACROLIMUS COMPOSITIONS FOR AEROSOL ADMINISTRATION 审中-公开
    用于气溶胶管理的TACROLIMUS组合物

    公开(公告)号：US20110318277A1

    公开(公告)日：2011-12-29

    申请号：US13168856

    申请日：2011-06-24

    申请人： Richard N. Dalby ,  Ralph Niven

    发明人： Richard N. Dalby ,  Ralph Niven

    IPC分类号： A61K9/12 ,  A61P37/06

    CPC分类号： A61K31/436 ,  A61K9/008

    摘要： The present disclosure relates generally to highly concentrated macrolide solutions for aerosol administration, and related methods of producing and administering the same. In one aspect, provided herein is a receptacle containing a highly concentrated solution of a macrolide compound such as tacrolimus, where the solution exhibits long-term stability in a pMDI canister and achieves high respirable fractions when actuated, among, other features. In yet another aspect, provided is a composition suitable for aerosol administration comprising tacrolimus dissolved in an ethanol-liquified propellant mixture, characterized by a tacrolimus concentration of greater than 0.15 weight percent (w/w) and comprising no more than about 10 weight percent (w/w) ethanol.

    摘要翻译： 本公开一般涉及用于气雾剂给药的高度浓缩的大环内酯溶液及其相关的生产和施用方法。 在一个方面，本文提供的是含有大环内酯类化合物如他克莫司的高度浓缩溶液的容器，其中溶液在pMDI罐中表现出长期稳定性，并且在致动时实现高呼吸成分，以及其它特征。 在另一方面，提供了适用于气溶胶施用的组合物，其包含溶解在乙醇液化的推进剂混合物中的他克莫司，其特征在于他克莫司浓度大于0.15重量％（w / w），并且包含不超过约10重量％ w / w）乙醇。

    Pulmonary surfactant formulations
    5.
    发明授权
    Pulmonary surfactant formulations 失效
    肺表面活性剂配方

    公开(公告)号：US08337815B2

    公开(公告)日：2012-12-25

    申请号：US11316308

    申请日：2005-12-21

    申请人： Maithili Rairkar ,  Rom E Eliaz ,  Ralph Niven ,  Mark E. Johnson

    发明人： Maithili Rairkar ,  Rom E Eliaz ,  Ralph Niven ,  Mark E. Johnson

    IPC分类号： A61K9/12 ,  A61K38/00

    CPC分类号： A61K31/685 ,  A61K9/0082 ,  A61K31/575 ,  A61K31/683 ,  A61K38/16 ,  A61K38/395 ,  A61K45/06 ,  C07K14/785 ,  A61K2300/00

    摘要： Synthetic pulmonary surfactant compositions comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid are provided. Methods for treating respiratory disease are also provided comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid.

    摘要翻译： 提供包含二棕榈酰磷脂酰胆碱，磷脂酰甘油和基本上中性脂质，并且基本上不含1-棕榈酰基2-油酰磷脂酰甘油和基本上不含棕榈酸的合成肺表面活性剂组合物。 还提供了治疗呼吸系统疾病的方法，包括施用治疗有效量的包含二棕榈酰磷脂酰胆碱，磷脂酰甘油和基本中性脂质的合成肺表面活性剂，并且基本上不含1-棕榈酰基2-油酰磷脂酰甘油并且基本上不含棕榈酸。

    Methods for introducing nucleic acids into mammalian cells using imidazolium lipids
    8.
    发明授权
    Methods for introducing nucleic acids into mammalian cells using imidazolium lipids 有权
    使用咪唑类脂质将核酸引入哺乳动物细胞的方法

    公开(公告)号：US06245520B1

    公开(公告)日：2001-06-12

    申请号：US09626268

    申请日：2000-07-25

    申请人： Jinkang Wang ,  Ralph Niven ,  Yilin Zhang ,  Pingzhong Huang

    发明人： Jinkang Wang ,  Ralph Niven ,  Yilin Zhang ,  Pingzhong Huang

    IPC分类号： A61K314164

    CPC分类号： C07D233/22 ,  C07D233/24

    摘要： Methods for introducing nucleic acids into mammalian cells are provided which use imidazolium lipids. The imidazolium lipids have the formula: wherein R1 and R2 each independently represent a C8-C24 saturated or unsaturated hydrocarbon chain, uninterrupted or interrupted by from 1 to 3 heteroatom moieties selected from —O—, —S—, —NH— and —NR—; X represents —CH2—, —O—, —S—, —NH— or —NR—; wherein R is a lower alkyl group having from 1 to 4 carbon atoms; n is an integer of from 1 to 2; and A− is an anion.

    摘要翻译： 提供了使用咪唑鎓脂质将核酸引入哺乳动物细胞的方法。 咪唑类脂质具有下式：其中R 1和R 2各自独立地代表C 8 -C 24饱和或不饱和的烃链，不间断或被1-3个选自-O - ， - S - ， - NH-和-NR - ; X表示-CH 2 - ， - O - ， - S - ， - NH-或-NR-; 其中R是具有1至4个碳原子的低级烷基; n为1〜2的整数， 而A-是阴离子。

    Pulmonary surfactant formulations
    10.
    发明申请
    Pulmonary surfactant formulations 失效
    肺表面活性剂配方

    公开(公告)号：US20060286038A1

    公开(公告)日：2006-12-21

    申请号：US11316308

    申请日：2005-12-21

    申请人： Maithili Rairkar ,  Rom Eliaz ,  Ralph Niven ,  Mark Johnson

    发明人： Maithili Rairkar ,  Rom Eliaz ,  Ralph Niven ,  Mark Johnson

    IPC分类号： A61K38/16 ,  A61L9/04 ,  A61K31/685 ,  A61K31/56

    CPC分类号： A61K31/685 ,  A61K9/0082 ,  A61K31/575 ,  A61K31/683 ,  A61K38/16 ,  A61K38/395 ,  A61K45/06 ,  C07K14/785 ,  A61K2300/00

    摘要： Synthetic pulmonary surfactant compositions comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid are provided. Methods for treating respiratory disease are also provided comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid.

    摘要翻译： 提供包含二棕榈酰磷脂酰胆碱，磷脂酰甘油和基本上中性脂质，并且基本上不含1-棕榈酰基2-油酰磷脂酰甘油和基本上不含棕榈酸的合成肺表面活性剂组合物。 还提供了治疗呼吸系统疾病的方法，包括施用治疗有效量的包含二棕榈酰磷脂酰胆碱，磷脂酰甘油和基本中性脂质的合成肺表面活性剂，并且基本上不含1-棕榈酰基2-油酰磷脂酰甘油并且基本上不含棕榈酸。